A case of Fanconi syndrome as a complication of treatment with a checkpoint inhibitor in a patient with hepatocellular carcinoma

Mohammad Tinawi; Bahar Bastani

doi:10.34172/jnp.2020.19

J Nephropathol. 2020;9(2): e19.
doi: 10.34172/jnp.2020.19

Scopus ID: 85079849086

Abstract View: 2444

PDF Download: 811

Case Report

A case of Fanconi syndrome as a complication of treatment with a checkpoint inhibitor in a patient with hepatocellular carcinoma

Mohammad Tinawi ¹, Bahar Bastani ²^*

¹ Nephrology Specialists, P.C. 801 MacArthur Blvd., Ste. 400A, Munster, IN 46321, USA
² Division of Nephrology, Saint Louis University Health Sciences Center, 3635 Vista Ave, St. Louis, MO, USA

*Corresponding Author: *Corresponding author: Prof. Bahar Bastani, M.D., Email: , Email: Bahar.Bastani@health.slu.edu

Abstract

Introduction: Immune checkpoint inhibitors (CPIs) represent novel new cancer immunotherapy agents. The use of nivolumab has been linked with immune mediated acute interstitial nephritis (AIN).

Case Presentation: We present the case of a patients with recurrent hepatocellular carcinoma who developed severe Fanconi syndrome, as evidenced by hyperchloremic metabolic acidosis, hypokalemia, hypophosphatemia, glucosuria, aminoaciduria, 8 months after initiating treatment with nivolumab, without any evidence of acute renal insufficiency.

Conclusion: Clinicians need to be aware of the renal side effects of new novel cancer immunotherapy agents, such as, immune CPIs

Keywords: Checkpoint inhibitors, Cancer immunotherapy, Fanconi syndrome, Hyperchloremic metabolic acidosis, Acute interstitial nephritis, Hepatocellular carcinoma

Implication for health policy/practice/research/medical education:

Clinicians need to be aware of the renal side effects of new novel cancer immunotherapy agents, such as, immune checkpoint inhibitors.

Please cite this paper as: Tinawi M, Bastani B. A case of Fanconi syndrome as a complication of treatment with a checkpoint inhibitor in a patient with hepatocellular carcinoma. J Nephropathol. 2020;9(2):e19. DOI: 10.34172/jnp.2020.19.